Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00176124
Other study ID # UniKlinMa-TF-2001-1
Secondary ID ISRCTN 99578441
Status Completed
Phase Phase 4
First received September 11, 2005
Last updated June 9, 2008
Start date April 2001
Est. completion date September 2005

Study information

Verified date June 2008
Source Heidelberg University
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

Leukocyte depletion of autologous whole blood prior to storage does not reduce infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay but may increase retransfusion perioperatively during hip arthroplasty and allogenic transfusion rate


Description:

Informed Consent Form:

Prior to the first blood donation, in- and exclusion criteria should be tested. Then the patient is to inform by the investigator about the studies aim and participation conditions such as methods, risks, assurance, data security, etc. The patient and the investigator should sign the informed consent form.

Randomization:

If all inclusion criteria are well given and exclusion criteria are absent, the patient could be enrolled and randomized, prior to the first PAD. Enrollment is parallel in all centers until the final number of 1088 is reached. Breaking the seal of the provided randomization envelope with computerized randomization codes completes randomization. Time and date should be noted.

Blinding:

Randomization is done by the investigator, which should manage the blood donation. The blood bags after inline leukocyte depletion prior to storage do not look different from not depleted bags and are labeled only with the patient's identity and the subjects ID. The allocation to the group is to keep secret from patient, surgeon and anesthesiologist.

Treatment:

A PAD:

Group 1 Preoperative Donation of multiple units ( more than 2) 450 mL autologous whole blood and storage without leukocyte depletion Usual criteria and methods of PAD are used according to regional guidelines of blood donations in the respective center.

Group 2 Preoperative Donation of multiple units (more than 2) 450 mL autologous whole blood and storage following leukocyte depletion 2 to 4 hours after whole blood donations, the whole blood bags should be in-line filtered by the use of leukocyte filtration sets (provided by Pall Medical Company). Storage as in group 1 at 4 degree C in a blood fridge.

A as proposal, the Mannheim concept reveals a 95 percent security in avoidance of allogenic transfusions for a blood loss of 20-25 ml per kg body weight: Intended are 3 donations in weekly intervals. If Hb plasma con-tent decreases below 11 g/dL, the donation will be postponed to the fol-lowing week. Surgery is at the fifth week after the first donation.

B Anesthesia and Surgery:

As usual in the center, and without a difference between the two groups anesthesia and surgery should be performed under following aspects:

- At hospital admission, the actual history should be taken, study measures (Appendix 1) and screening laboratory should be withdrawn prior to anesthesia to compute the infection risk assessment of the respective patient 13.

- Both general and regional (spinal or epidural anesthesia) can be performed

- Normothermia of the patients is essential to the infection rate, hypothermia increases the infection rate by every degree! The intra- and postoperative core temperature range will be requested.

- Circulatory monitoring should be performed according to the centers conventions. Monitoring with a 5 channel ECG is suggested. Normovolemia is essential because hypovolemia is related to increased infection rate by hypoperfusion of the wound14-16. Therefore, a central venous catheter is useful but not obligatory, but urine output is required since it is a more sensitive volume indicator in absence of significant heart and renal failure (and common practice in hip surgery). An arterial line is not obligatory required.

- Bladder catheter (Urine production more than 1ml/kg KG/h)

- Cell Savers and hemodilution (iso- or hypervolemic) are not accepted.

- Blood loss is to calculate carefully by subtracting rinsing from suction volumes and weighing sponges and drapes intraoperatively. Postoperatively the drainage volumes are sufficient if not massive expansion of thighs or hip occurs ( however, this should be noted as AE).

- In the case that allogenic transfusion is required additionally, this should be leukodepleted.

- Intra- und postoperative transfusion trigger are similar for autologous and allogenic transfusion:

- Hb greater than 8,5 plus minus 0,5

- HF over 100 plusminus 10 /min or 35% above base line

- MAP below 60 plusminus 5 mmHg or 35% below base line

- Stenocardia, chest pain

- ST-segment changes greater than 0,2 ms

Further documentation of

- ASA

- sex

- weight

- height

- Anesthesia duration

- OP-duration

- Blood loss(intra- and postoperatively)

- Lowest diastole. RR intraoperatively as well as postoperatively POD 0

- Time of transfusions

- Time of urine catheter withdrawal Infection-Monitoring

Parameter:

• Skin inspection

Criteria of wound infection:

- secretion clear or pus,

- pos. bacterial culture,

- erythema

- Urine culture if indicated by sediment (at withdrawl of bladder cathe-ter, discolored urine or fever)

- Blood culture (if fever above 39°C after POD2)

- Tracheal secretion (if expectoration is prutride or radiological indica-tion of bronchopneumonia)

- Antibiotic treatment, duration, amounts, multidrug use

Woundhealing and the occurrence of infections were classified with the ASEPSIS score: Of influence is the duration of antibiotic treatment, drainage of pus, wound de-bridements, erythema, involvement of deeper tissue layers, identification of bacteria, LOS above 14 days 17.

Infection Definition

Occurrence of any infection is defined as

- Elevation of patient's temperature/fever above 38°C on POD 3 or later or

- Leukocytosis above the cut off point (generated for every individual subject )or

- BSG / CRP above the cut off point (generated for every individual subject ) or

- Isolation of bacteria from any fluid including pus or

- Abscess (verificated by surgical drainage or ultrasonographically guided aspiration of pus ) or

- Arthritis by local clinical symptoms and surgical drainage

Wound infection is assessed by the ASEPSIS score

Urinary tract infection is defined as

- new isolated occurrence of leukocytosis, and/or nitrite, and/or protein or

- isolation of bacteria more than 10 000/µl (sediment) or

- growth of more than 100 000 colonies of a single organism in the culture

Respiratory airway infection is defined as

- positive x-ray (chest infiltrate) and fever or

- dyspnea or cough or purulent sputum and fever or

- isolation of bacteria in tracheal secretion (only intubated subjects) and fever

Septicemia is defined as

• clinical symptoms and positive blood culture


Recruitment information / eligibility

Status Completed
Enrollment 1089
Est. completion date September 2005
Est. primary completion date April 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- • ASA I-III,

- Age 18-85 years,

- Body weight 50-125 kg

- If female, with either a history of an accepted method of anticonception for at least 3 month prior and 1 month following the termination of the study or climacteric or with a negative betA- HCG-Test in urine or serum.

- Preoperative blood donation of at least 2 units (450mL whole blood)

- Preoperative hemoglobin level > 10 mg/dL

- Able and willing to sign informed consent

Exclusion Criteria:

- Subjects with a contraindication for preoperative blood donation (PAD) (in 12, PP 36-43).

- systemic infection

- acute bacterial or viral diseases

- anemia (Hb > 11g/dL)

- myocardial infarction within the past 6 month,

- instable angina pectoris

- vascular stenosis (i.e. of the coronary or internal carotid arteries)

- hemodynamic relevant valvular stenosis

- heart failure > NYHA II

- history of strokes or TIA

- steroid therapy,

- immune deficiency,

- hematological or endocrinological disease,

- coagulopathy,

- history of organ transplantation,

- simultaneous participation in a second study

- pregnancy

- membership at Jehovah's Witnesses

- intended use of a cell saver

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Procedure:
leukocyte depletion of whole blood

Other:
Leukocyte filtration/Depletion
leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours

Locations

Country Name City State
Germany Klinikum Garmisch Partenkirchen Garmisch Partenkirchen Bavaria
Germany Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine MAnnheim, University of Heidelberg, Germany Mannheim Baden-Wuerttemberg
Germany Institute of Transfusion Medicine and Hemostasiology, University of MArburg Marburg

Sponsors (2)

Lead Sponsor Collaborator
Heidelberg University Philipps University Marburg Medical Center

Country where clinical trial is conducted

Germany, 

References & Publications (6)

Byrne DJ, Malek MM, Davey PG, Cuschieri A. Postoperative wound scoring. Biomed Pharmacother. 1989;43(9):669-73. — View Citation

Frietsch T, Fessler H, Kirschfink M, Nebe T, Waschke KF, Lorentz A. Immune response to autologous transfusion in healthy volunteers: WB versus packed RBCs and FFP. Transfusion. 2001 Apr;41(4):470-6. Erratum in: Transfusion 2001 Jun;41(6):851. — View Citation

Frietsch T, Krombholz K, Tolksdorf B, Nebe T, Segiet W, Lorentz A. Cellular immune response to autologous blood transfusion in hip arthroplasty: whole blood versus buffy coat-poor packed red cells and fresh-frozen plasma. Vox Sang. 2001 Oct;81(3):187-93. — View Citation

Frietsch T, Lorentz A. Predonation of autologous blood is jeopardized by new regulations. Eur J Anaesthesiol. 2001 Oct;18(10):629-31. — View Citation

Lorentz A, Osswald PM, Schilling M, Jani L. [A comparison of autologous transfusion procedures in hip surgery]. Anaesthesist. 1991 Apr;40(4):205-13. German. — View Citation

Tolksdorf B, Frietsch T, Quintel M, Kirschfink M, Becker P, Lorentz A. Humoral immune response to autologous blood transfusion in hip surgery: whole blood versus packed red cells and plasma. Vox Sang. 2001 Oct;81(3):180-6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay 90 days Yes
Secondary Blood loss and transfusion rate 90 days Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3